Carerx Corporation · TSX:CRRX
Carerx — Q2 2022 Earnings Presentation
17 slides from Carerx's earnings presentation, Aug 15, 2022
Slide 1: Q2 2022 Earnings Call
Slide 2: Cautionary Statements
Cautionary Statements Forward Looking Statements Certain of the statements contained in this presentation are "forward looking information within the meaning of applicable Canadian securities legislation. Forward looking information includes, but is not limited to, business strategy, plans and other
Slide 3: David Murphy, President & Chief Executive Officer
David Murphy President & Chief Executive Officer
Slide 4: Continued strong growth in revenue and Adjusted EBITDA
Q2 2022 Continued strong growth in revenue and Adjusted EBITDA Contribution from organic growth Acquisition of Hogan LTC Pharmacy business (May 30 Commenced operations at new high-volume fulfillment centre in Oakville, ON
Slide 5: Q2 2022 Financial Highlights
Q2 2022 Financial Highlights From Continuing Operations (+/- compared to Q2 2021) (millions) Q2 2022 Revenue $96.9 +95% Adjusted EBITDA $8.8 +103% Adjusted EBITDA Margin 9.1% +40bps - Average beds serviced of 96,746: +82% vs Q2/21 * Growth driven by: * Acquisitions completed in 2021 * ~l month of co
Slide 6: Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '19 Q2 '20 Q2 '21
Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '19 Q2 '20 Q2 '21 Q2 '22
Slide 7: Continued Integration of Medical Pharmacies
Continued Integration of Medical Pharmacies August 23, 2021: Completed Acquisition of LTC Pharmacy Division of Medical Pharmacies + Added ~36,000 beds, serviced through 17 centres in Ontario & Western Canada + Further expanded Canado’s largest national platform * Further strengthened best-in-class o
Slide 8: Hogan: Adds Innovative Pharmacy Services Delivery Model
Hogan: Adds Innovative Pharmacy Services Delivery Model May 30, 2022: Completed Acquisition of Hogan Long-Term Care Pharmacy Added ~800 beds On closing, signed new 7-year contract with largest customer Expected to contribute run-rate annualized revenue of ~$4.0 M and Adj. EBITDA ~$0.6 M, prior to an
Slide 9: Customer Contract Update
Customer Contract Update Renewals with three of four largest customers, including two largest customers Represents ~18,000 beds Beds will be under contract for an average of 5.5 years from end of 2021 Expected offboarding of approximately 5,800 beds throughout the second half of 2022 as a result of
Slide 10: Andrew Mok, Chief Financial Officer
Andrew Mok Chief Financial Officer
Slide 11: • • • • Q2 2021 Q2 2022
• 110 • 100 90 80 70 60 • 50 40 • 30 20 10 0 Q2 2021 Q2 2022
Slide 12: • • • • • Q2 2021 Q2 2022
• 10 • 9 • 8 • 7 6 5 • 4 3 2 1 0 Q2 2021 Q2 2022
Slide 13: Net Loss
• Q2 2021 Q2 2022 0 -5 -10 • -15 -20 -25 -30 Net Loss
Slide 14: Balance Sheet
Balance Sheet (millions except ratio) * Ending cash balance and cash used in operations were impacted by the timing of working capital movements during Q2 2022 At June 30/22 Cash $15.2M Net Debt! $79.4M Net Debt to Adjusted EBITDA? 2.3Xx 14 1. Debt = borrowings (principal) not including November 201
Slide 15: David Murphy, President & Chief Executive Officer
David Murphy President & Chief Executive Officer
Slide 16: Continued Long-Term Growth Trajectory
Continued Long-Term Ss CareRx Growth Trajectory >97,000! beds * Continued confidence in organic growth prospects Robust business development pipeline New bed license allocations to existing customers Beds in Canada expected to double in 15 years Market Cpe Minis We) says Organic Growth & Acquisition
Slide 17: Questions
J *.. Questions , Wee Visit our website at www.carerx.ca | Follow @CareRx on Twitter $$ CareRx